ALX Oncology Holdings(ALXO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ALXO ALX Oncology Holdings

盘前交易 03-19 08:02:15 EDT

2.15

-0.02

-0.92%

盘前2.21

+0.06+2.79%

08:00 EDT

最高2.18	最低2.08	成交量80.02万
今开2.17	昨收2.17	日振幅4.61%
总市值2.82亿	流通市值2.26亿	总股本1.31亿
成交额171.85万	换手率0.76%	流通股本1.05亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ALXO","market":"US","secType":"STK","nameCN":"ALX Oncology Holdings","latestPrice":2.15,"timestamp":1773864000000,"preClose":2.17,"halted":0,"volume":800191,"hourTrading":{"tag":"盘前","latestPrice":2.21,"preClose":2.15,"latestTime":"08:00 EDT","volume":3038,"amount":6695.0146773999995,"timestamp":1773921609664,"change":0.06,"changeRate":0.027907,"amplitude":0.032558},"delay":0,"changeRate":-0.00921658986175116,"floatShares":105000000,"shares":131197113,"eps":-1.899999,"marketStatus":"盘前交易","change":-0.02,"latestTime":"03-19 08:02:15 EDT","open":2.17,"high":2.18,"low":2.08,"amount":1718502.994656,"amplitude":0.046083,"askPrice":2.21,"askSize":100,"bidPrice":2.09,"bidSize":90,"shortable":3,"etf":0,"ttmEps":-1.899999,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773927000000},"marketStatusCode":1,"adr":0,"listingDate":1594958400000,"exchange":"NASDAQ","adjPreClose":2.15,"preHourTrading":{"tag":"盘前","latestPrice":2.21,"preClose":2.15,"latestTime":"08:00 EDT","volume":3038,"amount":6695.0146773999995,"timestamp":1773921609664,"change":0.06,"changeRate":0.027907,"amplitude":0.032558},"postHourTrading":{"tag":"盘后","latestPrice":2.12,"preClose":2.15,"latestTime":"19:08 EDT","volume":3625,"amount":7778.75,"timestamp":1773875322868,"change":-0.03,"changeRate":-0.013953,"amplitude":0.013953},"volumeRatio":2.148053039720041,"impliedVol":2.9741,"impliedVolPercentile":0.932},"requestUrl":"/m/hq/s/ALXO","defaultTab":"news","newsList":[{"id":"2616536239","title":"Alx Oncology Holdings Inc.盘中异动 股价大涨5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616536239","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616536239?lang=zh_cn&edition=full","pubTime":"2026-03-04 02:03","pubTimestamp":1772561027,"startTime":"0","endTime":"0","summary":"北京时间2026年03月04日02时03分，Alx Oncology Holdings Inc.股票出现波动，股价急速拉升5.19%。截至发稿，该股报2.23美元/股，成交量26.4928万股，换手率0.20%，振幅9.39%。Alx Oncology Holdings Inc.股票所在的生物技术行业中，整体跌幅为1.56%。Alx Oncology Holdings Inc.公司简介：ALX Oncology Holdings Inc是一家临床阶段的免疫肿瘤公司，专注于帮助患者对抗癌症，开发一个基于蛋白质工程和肿瘤专业知识的候选产品管道，以CD47阻断剂evorpacept为首，目前处于1期和2期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304020347a447a7a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304020347a447a7a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ALXO"],"gpt_icon":0},{"id":"1148111909","title":"ALX Oncology Holdings公布2025年第四季度及全年财务业绩并更新公司动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1148111909","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148111909?lang=zh_cn&edition=full","pubTime":"2026-02-27 21:00","pubTimestamp":1772197220,"startTime":"0","endTime":"0","summary":"ALX Oncology Holdings（纳斯达克代码：ALXO）近期披露了其2025年第四季度及全年的财务报告，同时分享了公司最新的业务进展。财报数据显示，公司在关键财务指标上表现稳健，研发管线持续推进，展现了其在肿瘤免疫治疗领域的持续投入与战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALXO"],"gpt_icon":0},{"id":"2612425257","title":"Alx Oncology Holdings Inc.盘中异动 大幅拉升5.17%报2.44美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2612425257","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612425257?lang=zh_cn&edition=full","pubTime":"2026-02-20 00:54","pubTimestamp":1771520093,"startTime":"0","endTime":"0","summary":"北京时间2026年02月20日00时54分，Alx Oncology Holdings Inc.股票出现波动，股价急速拉升5.17%。Alx Oncology Holdings Inc.股票所在的生物技术行业中，整体跌幅为0.36%。Alx Oncology Holdings Inc.公司简介：ALX Oncology Holdings Inc是一家临床阶段的免疫肿瘤公司，专注于帮助患者对抗癌症，开发一个基于蛋白质工程和肿瘤专业知识的候选产品管道，以CD47阻断剂evorpacept为首，目前处于1期和2期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602200054539541799e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602200054539541799e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ALXO"],"gpt_icon":0},{"id":"1186061147","title":"新数据揭示CD47表达水平可预测ALX Oncology Evorpacept联合Ziihera（Zanidatamab-Hrii）治疗晚期HER2阳性乳腺癌的疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1186061147","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186061147?lang=zh_cn&edition=full","pubTime":"2026-01-30 21:17","pubTimestamp":1769779044,"startTime":"0","endTime":"0","summary":"最新研究数据显示，CD47生物标志物的表达水平可作为预测晚期HER2阳性乳腺癌患者对ALX Oncology Holdings（ALXO）旗下Evorpacept与Ziihera（Zanidatamab-Hrii）联合疗法临床反应的关键指标。该发现为精准医疗提供了新的分子分型依据，有望优化治疗人群筛选策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALXO"],"gpt_icon":0},{"id":"2606773666","title":"Alx Oncology Holdings Inc.盘中异动 早盘股价大涨5.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606773666","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606773666?lang=zh_cn&edition=full","pubTime":"2026-01-27 23:08","pubTimestamp":1769526497,"startTime":"0","endTime":"0","summary":"北京时间2026年01月27日23时08分，Alx Oncology Holdings Inc.股票出现异动，股价快速拉升5.41%。Alx Oncology Holdings Inc.股票所在的生物技术行业中，整体涨幅为0.91%。Alx Oncology Holdings Inc.公司简介：ALX Oncology Holdings Inc是一家临床阶段的免疫肿瘤公司，专注于帮助患者对抗癌症，开发一个基于蛋白质工程和肿瘤专业知识的候选产品管道，以CD47阻断剂evorpacept为首，目前处于1期和2期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127230817a45ca307&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127230817a45ca307&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ALXO"],"gpt_icon":0},{"id":"2603785939","title":"Alx Oncology Holdings Inc.盘中异动 股价大涨5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603785939","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603785939?lang=zh_cn&edition=full","pubTime":"2026-01-15 22:34","pubTimestamp":1768487667,"startTime":"0","endTime":"0","summary":"北京时间2026年01月15日22时34分，Alx Oncology Holdings Inc.股票出现波动，股价急速上涨5.26%。Alx Oncology Holdings Inc.股票所在的生物技术行业中，整体跌幅为0.07%。Alx Oncology Holdings Inc.公司简介：ALX Oncology Holdings Inc是一家临床阶段的免疫肿瘤公司，专注于帮助患者对抗癌症，开发一个基于蛋白质工程和肿瘤专业知识的候选产品管道，以CD47阻断剂evorpacept为首，目前处于1期和2期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011522342797a1fc83&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011522342797a1fc83&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALXO","BK4139"],"gpt_icon":0},{"id":"2602489582","title":"Alx Oncology Holdings Inc.盘中异动 快速上涨5.65%报1.31美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602489582","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602489582?lang=zh_cn&edition=full","pubTime":"2026-01-09 22:35","pubTimestamp":1767969350,"startTime":"0","endTime":"0","summary":"北京时间2026年01月09日22时35分，Alx Oncology Holdings Inc.股票出现波动，股价大幅上涨5.65%。Alx Oncology Holdings Inc.股票所在的生物技术行业中，整体涨幅为0.76%。Alx Oncology Holdings Inc.公司简介：ALX Oncology Holdings Inc是一家临床阶段的免疫肿瘤公司，专注于帮助患者对抗癌症，开发一个基于蛋白质工程和肿瘤专业知识的候选产品管道，以CD47阻断剂evorpacept为首，目前处于1期和2期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010922355197a155fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010922355197a155fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ALXO"],"gpt_icon":0},{"id":"1136686782","title":"ALX Oncology推进评估试验性CD47抑制剂Evorpacept及新型EGFR靶向抗体偶联药物ALX2004的独立临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1136686782","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136686782?lang=zh_cn&edition=full","pubTime":"2026-01-08 21:33","pubTimestamp":1767879222,"startTime":"0","endTime":"0","summary":"ALX Oncology Holdings（ALXO）宣布同步推进两项独立临床试验的进展。其中一项试验旨在评估其研发的CD47抑制剂Evorpacept的疗效与安全性，另一项试验则聚焦于新型EGFR靶向抗体偶联药物ALX2004的临床验证。\n这两项试验分别针对不同的肿瘤治疗机制。Evorpacept通过阻断CD47信号通路激活先天免疫系统，ALX2004则利用抗体偶联技术精准靶向EGFR高表达肿瘤细胞。公司表示，临床试验的并行推进将加速创新抗癌疗法的开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALXO","BK4139"],"gpt_icon":0},{"id":"2601802822","title":"Alx Oncology Holdings Inc.盘中异动 快速拉升5.56%报1.14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601802822","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601802822?lang=zh_cn&edition=full","pubTime":"2026-01-07 22:48","pubTimestamp":1767797301,"startTime":"0","endTime":"0","summary":"北京时间2026年01月07日22时48分，Alx Oncology Holdings Inc.股票出现波动，股价快速拉升5.56%。Alx Oncology Holdings Inc.股票所在的生物技术行业中，整体涨幅为1.72%。Alx Oncology Holdings Inc.公司简介：ALX Oncology Holdings Inc是一家临床阶段的免疫肿瘤公司，专注于帮助患者对抗癌症，开发一个基于蛋白质工程和肿瘤专业知识的候选产品管道，以CD47阻断剂evorpacept为首，目前处于1期和2期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107224821953c294b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107224821953c294b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALXO","BK4139"],"gpt_icon":0},{"id":"1183115403","title":"ALX Oncology公布Evorpacept与标准治疗联合应用于惰性B细胞非霍奇金淋巴瘤患者的积极试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1183115403","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183115403?lang=zh_cn&edition=full","pubTime":"2025-12-07 21:06","pubTimestamp":1765112805,"startTime":"0","endTime":"0","summary":"ALX Oncology公布Evorpacept与标准治疗联合应用于惰性B细胞非霍奇金淋巴瘤患者的积极试验结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALXO","BK4139"],"gpt_icon":0},{"id":"2578241570","title":"Alx Oncology Holdings Inc.盘中异动 大幅拉升5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578241570","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578241570?lang=zh_cn&edition=full","pubTime":"2025-10-24 21:50","pubTimestamp":1761313835,"startTime":"0","endTime":"0","summary":"北京时间2025年10月24日21时50分，Alx Oncology Holdings Inc.股票出现异动，股价急速上涨5.14%。截至发稿，该股报1.84美元/股，成交量8.0498万股，换手率0.15%，振幅5.14%。Alx Oncology Holdings Inc.股票所在的生物技术行业中，整体涨幅为0.30%。Alx Oncology Holdings Inc.公司简介：ALX Oncology Holdings Inc是一家临床阶段的免疫肿瘤公司，专注于帮助患者对抗癌症，开发一个基于蛋白质工程和肿瘤专业知识的候选产品管道，以CD47阻断剂evorpacept为首，目前处于1期和2期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024215035a6cc36df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024215035a6cc36df&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ALXO"],"gpt_icon":0},{"id":"1115319102","title":"ALX Oncology在2025年AACR-NCI-EORTC会议上宣布Alx2004的前临床数据及I期试验进展报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1115319102","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115319102?lang=zh_cn&edition=full","pubTime":"2025-10-24 00:31","pubTimestamp":1761237070,"startTime":"0","endTime":"0","summary":"ALX Oncology在2025年AACR-NCI-EORTC会议上公布了Alx2004的前临床数据以及I期试验进展报告，这是一种新型的EGFR靶向ADC。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALXO"],"gpt_icon":0},{"id":"2577806468","title":"Alx Oncology Holdings Inc.盘中异动 大幅上涨5.45%报1.74美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2577806468","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577806468?lang=zh_cn&edition=full","pubTime":"2025-10-21 21:30","pubTimestamp":1761053437,"startTime":"0","endTime":"0","summary":"北京时间2025年10月21日21时30分，Alx Oncology Holdings Inc.股票出现异动，股价大幅拉升5.45%。Alx Oncology Holdings Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Alx Oncology Holdings Inc.公司简介：ALX Oncology Holdings Inc是一家临床阶段的免疫肿瘤公司，专注于帮助患者对抗癌症，开发一个基于蛋白质工程和肿瘤专业知识的候选产品管道，以CD47阻断剂evorpacept为首，目前处于1期和2期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251021213037a46c7a31&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251021213037a46c7a31&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALXO","BK4139"],"gpt_icon":0},{"id":"2570080105","title":"Alx Oncology Holdings Inc.盘中异动 早盘股价大涨5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2570080105","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570080105?lang=zh_cn&edition=full","pubTime":"2025-09-24 22:08","pubTimestamp":1758722903,"startTime":"0","endTime":"0","summary":"北京时间2025年09月24日22时08分，Alx Oncology Holdings Inc.股票出现波动，股价快速拉升5.16%。截至发稿，该股报1.33美元/股，成交量5.1018万股，换手率0.10%，振幅2.30%。Alx Oncology Holdings Inc.股票所在的生物技术行业中，整体跌幅为0.10%。Alx Oncology Holdings Inc.公司简介：ALX Oncology Holdings Inc是一家临床阶段的免疫肿瘤公司，专注于帮助患者对抗癌症，开发一个基于蛋白质工程和肿瘤专业知识的候选产品管道，以CD47阻断剂evorpacept为首，目前处于1期和2期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924220823a4414cae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924220823a4414cae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ALXO"],"gpt_icon":0},{"id":"2569756418","title":"Alx Oncology Holdings Inc.盘中异动 早盘急速下挫5.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2569756418","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569756418?lang=zh_cn&edition=full","pubTime":"2025-09-22 21:37","pubTimestamp":1758548279,"startTime":"0","endTime":"0","summary":"北京时间2025年09月22日21时37分，Alx Oncology Holdings Inc.股票出现波动，股价大幅下挫5.78%。Alx Oncology Holdings Inc.股票所在的生物技术行业中，整体跌幅为0.10%。Alx Oncology Holdings Inc.公司简介：ALX Oncology Holdings Inc是一家临床阶段的免疫肿瘤公司，专注于帮助患者对抗癌症，开发一个基于蛋白质工程和肿瘤专业知识的候选产品管道，以CD47阻断剂evorpacept为首，目前处于1期和2期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922213759a72f8822&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922213759a72f8822&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALXO","BK4139"],"gpt_icon":0},{"id":"2518274387","title":"Alx Oncology Holdings Inc.盘中异动 早盘急速跳水5.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518274387","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518274387?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:59","pubTimestamp":1741618792,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时59分，Alx Oncology Holdings Inc.股票出现波动，股价急速下挫5.60%。截至发稿，该股报1.00美元/股，成交量42.57万股，换手率0.80%，振幅6.60%。Alx Oncology Holdings Inc.股票所在的生物技术行业中，整体涨幅为0.40%。Alx Oncology Holdings Inc.公司简介：ALX Oncology Holdings Inc是一家临床阶段的免疫肿瘤公司，专注于帮助患者对抗癌症，开发一个基于蛋白质工程和肿瘤专业知识的候选产品管道，以CD47阻断剂evorpacept为首，目前处于1期和2期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310225952abf31d3d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310225952abf31d3d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALXO","BK4139"],"gpt_icon":0},{"id":"2518849482","title":"Alx Oncology Holdings Inc.2024财年实现净利润-1.35亿美元，同比增加16.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518849482","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518849482?lang=zh_cn&edition=full","pubTime":"2025-03-10 00:01","pubTimestamp":1741536075,"startTime":"0","endTime":"0","summary":"3月10日，Alx Oncology Holdings Inc.公布财报，公告显示公司2024财年净利润为-1.35亿美元，同比增加16.15%；其中营业收入为0.00美元，每股基本收益为-2.58美元。从资产负债表来看，Alx Oncology Holdings Inc.总负债34.16百万美元，其中短期债务2.35百万美元，资产负债比为0.05，流动比率为0.08。机构评级：截至2025年3月10日，当前有5家机构对Alx Oncology Holdings Inc.目标价做出预测，其中目标均价为4.14美元，其中最低目标价为1.50美元，最高目标价为9.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000233abf1756a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000233abf1756a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALXO"],"gpt_icon":0},{"id":"2517453312","title":"Stifel：维持ALX Oncology Holdings(ALXO.US)评级，由持有调整至持有评级, 目标价由3.00美元调整至1.50美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517453312","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517453312?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:52","pubTimestamp":1741366373,"startTime":"0","endTime":"0","summary":"Stifel：维持ALX Oncology Holdings(ALXO.US)评级，由持有调整至持有评级, 目标价由3.00美元调整至1.50美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08005248604793.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ALX","ALXO"],"gpt_icon":0},{"id":"1152886927","title":"ALX Oncology Holdings 2024财年第四季度调整后每股收益$(0.44)，好于预期的$(0.67)","url":"https://stock-news.laohu8.com/highlight/detail?id=1152886927","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152886927?lang=zh_cn&edition=full","pubTime":"2025-03-07 05:19","pubTimestamp":1741295978,"startTime":"0","endTime":"0","summary":"ALX Oncology Holdings 报告称季度每股亏损$，好于分析师一致预期的$，高出34.33%。这比去年同期每股亏损$增加了44.3%。以上内容来自Benzinga Earnings专栏，原文如下：$ALX Oncology Holdings$  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 34.33 percent. This is a 44.3 percent increase over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALX","ALXO"],"gpt_icon":0},{"id":"2517655561","title":"Alx Oncology Holdings Inc.盘中异动 早盘大幅拉升5.29%报1.10美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517655561","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517655561?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:31","pubTimestamp":1741271470,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时31分，Alx Oncology Holdings Inc.股票出现异动，股价急速拉升5.29%。截至发稿，该股报1.10美元/股，成交量36.2202万股，换手率0.69%，振幅1.92%。Alx Oncology Holdings Inc.股票所在的生物技术行业中，整体跌幅为0.63%。Alx Oncology Holdings Inc.公司简介：ALX Oncology Holdings Inc是一家临床阶段的免疫肿瘤公司，专注于帮助患者对抗癌症，开发一个基于蛋白质工程和肿瘤专业知识的候选产品管道，以CD47阻断剂evorpacept为首，目前处于1期和2期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223110989eb3d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223110989eb3d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ALXO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alxoncology.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.0271},{"period":"3month","weight":0.5248},{"period":"6month","weight":0.7769},{"period":"1year","weight":1.898},{"period":"ytd","weight":0.9027}],"compareEarnings":[{"period":"1week","weight":-0.022},{"period":"1month","weight":-0.0298},{"period":"3month","weight":-0.0222},{"period":"6month","weight":-0.0034},{"period":"1year","weight":0.179},{"period":"ytd","weight":-0.03}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"ALX Oncology Holdings Inc.于2020年4月1日成立。该公司是一家临床阶段的免疫肿瘤学公司，专注于通过开发阻断CD47免疫检查点和连接先天和适应性免疫系统的疗法来帮助患者对抗癌症。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.021509},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.026406},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.186792},{"month":4,"riseRate":0.4,"avgChangeRate":0.062669},{"month":5,"riseRate":0.2,"avgChangeRate":-0.170133},{"month":6,"riseRate":0.4,"avgChangeRate":-0.086057},{"month":7,"riseRate":0.6,"avgChangeRate":0.048848},{"month":8,"riseRate":0.666667,"avgChangeRate":0.169542},{"month":9,"riseRate":0.5,"avgChangeRate":0.033313},{"month":10,"riseRate":0.5,"avgChangeRate":0.033571},{"month":11,"riseRate":0.5,"avgChangeRate":0.074796},{"month":12,"riseRate":0.666667,"avgChangeRate":0.109411}],"exchange":"NASDAQ","name":"ALX Oncology Holdings","nameEN":"ALX Oncology Holdings"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ALX Oncology Holdings(ALXO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ALX Oncology Holdings(ALXO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ALX Oncology Holdings,ALXO,ALX Oncology Holdings股票,ALX Oncology Holdings股票老虎,ALX Oncology Holdings股票老虎国际,ALX Oncology Holdings行情,ALX Oncology Holdings股票行情,ALX Oncology Holdings股价,ALX Oncology Holdings股市,ALX Oncology Holdings股票价格,ALX Oncology Holdings股票交易,ALX Oncology Holdings股票购买,ALX Oncology Holdings股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ALX Oncology Holdings(ALXO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ALX Oncology Holdings(ALXO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}